Healthcare institutions participating in the 340B Drug Pricing Program should understand three critical developments. First, pharmaceutical manufacturers like Eli Lilly are now actively enforcing claims data reporting requirements by terminating discounts for non-compliant hospitals—a significant shift from previous oversight practices. Second, smaller and rural hospitals may be disproportionately affected, as 72 percent report inadequate IT infrastructure to meet compliance demands, creating a potential two-tiered system where well-resourced institutions retain discounts while underfunded ones lose access.
Third, these enforcement actions carry direct consequences for patient care. Uninsured populations treated at safety-net hospitals face heightened risk of reduced medication access and increased out-of-pocket costs when institutions lose programme benefits. Healthcare leaders must now prioritize investment in data reporting infrastructure, staff training, and claims management systems to maintain 340B eligibility and protect vulnerable patient populations from medication cost barriers. Read the full article on GMJ Newsroom.
Was this article helpful?
